Why the study?
Does single-dose CS-866 reduce blood pressure and alter endocrine parameters in salt-restricted patients with mild-to-moderate hypertension?
Population
16 patients with mild-to-moderate hypertension on a sodium-restricted diet
Comparison
Single oral doses of CS-866 vs Placebo
Design
Other
Follow-up
24 hours
Authors
Loading...
Supports single-dose CS-866 for BP lowering in salt-restricted hypertensives; confirms efficacy of this novel angiotensin II antagonist in RCT.
Does single-dose CS-866 reduce blood pressure and alter endocrine parameters in salt-restricted patients with mild-to-moderate hypertension?
Single oral doses of 10-20 mg of the novel Ang II antagonist CS-866 effectively lower blood pressure in salt-restricted hypertensive patients.
Püchler et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: